CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN)
Decision follows positive recommendation from Committee for Medicinal Products for Human Use (CHMP) from February 2025
EU approval is based on the complete data set from the phase-III PROTECT study
ST. GALLEN, Switzerland and SAN DIEGO, April 29, 2025 /CNW/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing authorization (MA) for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). Standard MA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
"The decision by the European Commission is an important advancement for people living with IgAN in the EU", said Dr. Vinicius Gomes De Lima, Head of Global Medical Affairs at CSL Vifor. "The standard approval, granted without changes to the indication, underscores the value of our clinical data, the dedication of our teams, and our ongoing commitment to deliver on our promise for patients. We look forward to continuing working closely with healthcare professionals, patient communities, and regulatory bodies to ensure access to FILSPARI across Europe."
The European Commission's standard approval of FILSPARI is a meaningful step forward for people living with IgA nephropathy across Europe," said Dr. Jula Inrig, Chief Medical Officer at Travere Therapeutics. "This decision not only validates the strength of the phase-III PROTECT study results but also reinforces our deep commitment to this rare kidney disease community. We remain dedicated to working with our partners, regulators, and healthcare providers to expand access and improve outcomes for those affected by IgAN."
The European Commission's decision follows CHMP's recommendation to convert the CMA to standard MA from February 2025. The approval is based on a comprehensive clinical data set, including positive confirmatory results from the pivotal phase-III PROTECT study demonstrating that FILSPARI significantly slowed kidney function decline over two years compared to irbesartan.
FILSPARI is the only Dual Endothelin Angiotensin Receptor Antagonist (DEARA), a non-immunosuppressive therapy for the treatment of IgAN approved in Europe and is currently available in Germany, Austria and Switzerland, following the European Commission's conditional marketing authorization in April 2024
About CSL Vifor
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
The parent company, CSL (ASX: CSL; USOTC: CSLLY), headquartered in Melbourne, Australia, employs 32,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, cslvifor.com.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
About IgA Nephropathy (IgAN)
IgAN, also called Berger's disease, is a rare progressive kidney disease characterized by the buildup of immunoglobulin A (IgA), a protein that helps the body fight infections, in the kidneys. The deposits of IgA cause a breakdown of the normal filtering mechanisms in the kidney, leading to blood in the urine (hematuria), protein in the urine (proteinuria) and a progressive loss of kidney function. Other symptoms of IgAN may include swelling (edema) and high blood pressure.
While rare, IgAN is the most common type of primary glomerular disease worldwide and a leading cause of kidney failure. IgAN is estimated to affect up to 250,000 people in the licensed territories (Europe, Australia and New Zealand).
About the PROTECT study
The PROTECT Study is one of the largest interventional studies to date in IgA nephropathy (IgAN) and the only head-to-head vs. comparator trial in this rare kidney disease. It is a global, randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial evaluating the safety and efficacy of 400 mg of sparsentan, compared to 300 mg of irbesartan (an angiotensin II receptor blocker(ARB)), in 404 patients ages 18 years and up with IgA nephropathy and persistent proteinuria despite receiving at least 50% of maximum label dose and maximally tolerated angiotensin-converting enzyme (ACE) inhibitors or ARB therapy.
The PROTECT study met its primary endpoint at the pre-specified interim analysis with statistical significance. After 36 weeks of treatment, patients receiving FILSPARI achieved a mean reduction in proteinuria from baseline of 49.8 percent, compared to a mean reduction in proteinuria from baseline of 15.1 percent for irbesartan-treated patients. The two-year confirmatory results from the study showed treatment with FILSPARI achieved statistical significance on the eGFR chronic slope endpoint versus irbesartan and demonstrated clinically meaningful kidney function preservation. eGFR is a blood test that measure how well kidneys filter waste products from blood. Treatment emergent adverse events were well-balanced between sparsentan and irbesartan, except for dizziness and hypotension.
About FILSPARI (sparsentan)
FILSPARI is an innovative, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist with high selectivity for the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R).
FILSPARI was developed by Travere Therapeutics and has been granted Orphan Drug Designation for the treatment of IgA nephropathy in the UK, Europe and the U.S. FILSPARI is currently available in the U.S. and first markets in Europe. CSL Vifor has been granted exclusive commercialization rights for FILSPARI in Europe, Australia and New Zealand.
For more information, please refer to the Summary of Product Characteristics (SmPC).
CSL Vifor Media Contact
Travere Therapeutics:
Investors
888-969-7879
[email protected]
Media
888-969-7879
[email protected]
SOURCE Vifor International AG (CSL Vifor)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 days ago
- Globe and Mail
Poland Data Center Market Investment to Reach USD 2.78 Billion by 2030 – Exclusive Research Report by Arizton
"Poland Data Center Market Research Report by Arizton" Get Insights on 65 Existing Data Centers and Facilities across Poland According to Arizton's latest research report, the Poland data center market growing at a CAGR of 15.73% during 2024-2030. Report Summary Market Size (Investment): USD 2.78 Billion (2030) Market Size (Area): 342 Thousand Sq. Feet (2030) Market Size (Power Capacity): 76 MW (2030) CAGR - Investment (2024-2030): 15.73% Colocation Market Size (Revenue): USD 942 Million (2030) Historic Year: 2021-2023 Base Year: 2024 Forecast Year: 2025-2030 Poland Emerges as a Strategic Hub for AI-Driven Data Center Development Poland is rapidly emerging as a prominent data center hub in Europe, driven by the accelerating adoption of artificial intelligence (AI) across key sectors such as agriculture, healthcare, finance, manufacturing, transportation, retail, and public services. With strong support from the Polish government, AI is becoming a core pillar of national innovation strategy. In February 2025, the government signed a Memorandum of Understanding (MoU) with Google to boost the development and application of AI technologies across sectors including energy and cybersecurity, marking a major step in cross-sector digital advancement. Further strengthening Poland's AI ecosystem, the European Commission announced in March 2025 the establishment of six AI factories across Europe one of which will be located in Poland. The Piast AI Factory, set to be developed at the Poznań Supercomputing and Networking Center (PCSS), represents a joint investment of approximately $143 million, with $53 million contributed by the European Commission and $90 million from the Polish government. As AI becomes a central pillar of digital transformation, data center operators in Poland are proactively developing facilities designed to meet the unique infrastructure needs of AI technologies. Poland Advances Renewable Energy Procurement Amid Growing Digital Demand Poland is richly endowed with renewable energy resources, including solar, wind, and bioenergy, positioning the country for a sustainable energy transition. In 2024, renewables accounted for approximately 29% of Poland's power generation, reflecting strong progress toward its ambitious goal of achieving net-zero emissions by 2050. As demand for digital services rises, driving increased electricity consumption by data centers, Poland is concurrently emphasizing sustainable energy solutions to meet this growing need responsibly. While fossil fuels remain the primary energy source, the government has launched targeted initiatives to reduce coal dependency and accelerate the adoption of renewable sources, primarily solar and wind. Government support and rising awareness of sustainable energy have fueled continuous growth in renewable energy demand, reinforcing Poland's commitment to a greener energy future and supporting the expansion of energy-intensive digital infrastructure. Recent Vendor Activities In February 2025, Microsoft announced its plans to invest around $740 million in expanding its AI infrastructure in Poland by 2026. In October 2024, Google Cloud launched confidential computing instances based on Intel Xeon and AMD Epyc processors providing enhanced data security by encrypting data during processing. Poland Accelerates Digital Transformation with Big Data and IoT Innovations Poland is witnessing a robust surge in the adoption of big data and IoT technologies across a diverse range of industries, including automotive, smart finance, education, and manufacturing. This digital momentum is exemplified by initiatives such as the Greater Poland IoT project, which integrates a sophisticated multimodal sensory network spanning multiple cities. Developed by the Institute of Logistics and Warehousing in collaboration with partners like Talex, PSNC, Inwebit, Sonalake, and Zeto, this project showcases the country's commitment to advancing smart, connected solutions. Supporting this growth, IoT SIM cards in Poland offer cost-effective, multi-network connectivity across leading providers such as Orange Poland, Play, and, ensuring reliable coverage on 2G, 3G, and LTE networks, critical for seamless IoT applications. With strong backing from both private enterprises and government initiatives, demand for IoT and big data solutions is projected to rise sharply over the next three to four years. Industries across the board are increasingly leveraging these technologies to enhance operational efficiency and enable precise data-driven insights. This escalating push toward digitalization is expected to significantly boost data traffic nationwide, fueling a parallel increase in demand for advanced data center infrastructure, solidifying Poland's position as a key player in Europe's digital future. Warsaw Leads Poland's Data Center and Cloud Infrastructure Growth Warsaw is rapidly establishing itself as the epicenter of data center and cloud infrastructure development in Poland, driven by its strategic location, robust connectivity, and well-developed urban infrastructure. With the highest concentration of data centers—approximately 30 facilities—the city hosts leading providers such as Equinix, Atman, Data4, Netia, 3S, T-Mobile, and Vantage Data Centers. The momentum is accelerating. Between 2025 and 2030, Warsaw's data center market is expected to grow at a cumulative rate of approximately 67%, making it the dominant force in Poland's digital infrastructure landscape. In April 2024, Atman secured a significant investment of $345 million from six Polish and European financial institutions to expand its data center footprint in Warsaw and other key regions. Warsaw's thriving ecosystem of large enterprises in finance, media, and entertainment is also driving demand for cloud-based services and emerging technologies such as AI, machine learning, big data, and IoT. This digital transformation has attracted attention from global hyperscalers; in February 2025, Microsoft announced a $700 million investment to expand its existing facility and bring Azure cloud services to the city. The Report Includes the Investment in the Following Areas: IT Infrastructure Servers Storage Systems Network Infrastructure Electrical Infrastructure UPS Systems Generators Transfer Switches & Switchgears PDUs Other Electrical Infrastructure Mechanical Infrastructure Cooling Systems Rack Cabinets Other Mechanical Infrastructure Cooling Systems CRAC & CRAH Units Chiller Units Cooling Towers, Condensers & Dry Coolers Other Cooling Units General Construction Core & Shell Development Installation & Commissioning Services Engineering & Building Design Fire Detection & Suppression Systems Physical Security DCIM Tier Standard Tier I & Tier II Tier III Tier IV Geography Warsaw Other Cities Vendor Landscape IT Infrastructure Providers Atos Cisco Systems Dell Technologies Fujitsu Hewlett Packard Enterprise Hitachi Vantara Huawei Technologies IBM Inspur Juniper Networks Lenovo NetApp Pure Storage Data Center Construction Contractors & Sub-Contractors AODC PORR Group Warbud STRABAG Techko Turner & Townsend Support Infrastructure Providers 3M ABB AERMEC Airedale by Modine Alfa Laval Carrier Caterpillar Condair Cummins Daikin Applied Delta Electronics Eaton HITEC Power Protection Johnson Controls Legrand Mitsubishi Electric Perkins Engines Pillar Power Systems Rittal Rolls-Royce Schneider Electric Siemens STULZ Vertiv Data Center Investors 3S Group Adgar Investments & Development Atman Data4 Equinix Exea Data Center Microsoft Netia Orange Business Polcom Talex T-Mobile Vantage Data Centers Other Related Reports that Might be of Your Business Requirement Europe Data Center Market Landscape 2025–2030 Global Data Center Cooling Market Landscape 2025-2030 Key Questions Answered in the Report: How big is the Poland data center market? How many existing and upcoming data center facilities exist in Poland? What is the growth rate of the Poland data center market? How much MW of power capacity will be added across Poland during 2025-2030? Who are the key investors in the Poland data center market? What factors are driving the Poland data center market? Why Arizton? 100% Customer Satisfaction 24x7 availability – we are always there when you need us 200+ Fortune 500 Companies trust Arizton's report 80% of our reports are exclusive and first in the industry 100% more data and analysis 1500+ reports published till date Post-Purchase Benefit 1hr of free analyst discussion 10% off on customization About Us: Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services. We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts. Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
CBC
3 days ago
- CBC
Consumer group accuses Shein of manipulating shoppers with 'dark patterns'
Social Sharing A consumer organization filed a complaint with the European Commission on Thursday against online fast-fashion retailer Shein over its use of "dark patterns," which are tactics designed to make people buy more on its app and website. Pop-ups urging customers not to leave the app or risk losing promotions, countdown timers that create time pressure to complete a purchase and the infinite scroll on its app are among the methods Shein uses that could be considered "aggressive commercial practices," wrote BEUC, a pan-European consumer group, in a report. The BEUC also detailed Shein's use of frequent notifications, with one phone receiving 12 notifications from the app in a single day. "For fast fashion you need to have volume, you need to have mass consumption, and these dark patterns are designed to stimulate mass consumption," said Agustin Reyna, director general of BEUC, in an interview. "For us, to be satisfactory they need to get rid of these dark patterns, but the question is whether they will have enough incentive to do so, knowing the potential impact it can have on the volume of purchases." WATCH | How dark patterns are regulated by Canadian law: How dark patterns in web design are regulated under Canadian law 2 years ago Duration 2:09 A U.S. regulator sued Amazon last month for allegedly duping customers into buying Prime memberships using a web design trick called 'dark patterns.' Here's what Canada is doing about the practice. A Shein spokesperson said in a statement that the company is "already working constructively with national consumers authorities and the EU Commission to demonstrate our commitment to complying with EU laws and regulations." It added that the BEUC had not accepted its request for a meeting. Gameification used to drive shoppers to app The BEUC also targeted the online discount platform Temu, a Shein rival, in a previous complaint. Both platforms have surged in popularity in Europe, partly helped by apps that encourage shoppers to engage with games and stand to win discounts and free products. Shein's use of gameification, drawing shoppers to use the app regularly, has helped drive its success. In the "Puppy Keep" game on the app, users feed a virtual dog and collect points to win free items. They can gain more points by scrolling through the app, and by ordering items, but must log into the game every day or risk losing cumulative rewards. The BEUC noted that dark patterns are widely used by mass-market clothing retailers and called on the consumer protection network to include other retailers in its investigation. It said 25 of its member organizations in 21 countries, including France, Germany and Spain, joined in the grievance filed with the commission and with the European consumer protection network. Late last month, the European Commission notified Shein of practices breaching EU consumer law and warned it would face fines if it failed to address the concerns.
Cision Canada
3 days ago
- Cision Canada
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 4, 2025 /CNW/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN). Findings presented today at the 62 nd ERA Congress demonstrate sustained proteinuria remission, stable kidney function, and a reassuring safety profile. IgAN is the most common form of glomerular disease worldwide and a frequent cause of chronic kidney disease. Its pathogenesis is marked by inflammation and progressive kidney damage, which can lead to kidney failure. Many patients are unaware they have the condition until significant kidney damage has occurred, and 50% of IgAN patients will ultimately develop kidney failure. By targeting the APRIL pathway and reducing production of pathogenic galactose-debecause ofgA1), zigakibart addresses a key driver of disease progression. "Zigakibart is designed to intercept the initiating factor in IgAN pathogenesis, offering a new approach that may halt or significantly delay progression", explained lead investigator Professor Jonathan Barratt. The ADU-CL-19 trial included 40 adults with biopsy-confirmed IgAN and persistent proteinuria despite stable supportive therapy. Patients received zigakibart every two weeks via intravenous infusion or subcutaneous injection, in addition to maximally tolerated renin–angiotensin system inhibitors (RASi) unless RASi-intolerant – demonstrating efficacy beyond standard care. At Week 100, proteinuria was reduced by 60% from baseline. Over half of patients (55%) reached <500 mg/24 h, and 31% achieved <300 mg/24 h, indicating deeper remission. Estimated glomerular filtration rate (eGFR) remained stable across subgroups. "The consistency of eGFR stabilisation over 100 weeks, even across proteinuria response groups, is particularly encouraging," said Prof. Barratt. Treatment also led to sustained reductions in serum immunoglobulins, including a 74% drop in IgA and pathogenic Gd-IgA1, consistent with APRIL pathway inhibition. Zigakibart was well tolerated throughout. Most adverse events were mild or moderate, with no treatment-related serious infections or discontinuations. Infections were the most common AEs; the study coincided with a high prevalence of COVID-19. This is the longest duration of eGFR stabilisation reported for an anti-APRIL agent in IgAN. "These long-term results build confidence in zigakibart as a potential cornerstone therapy for IgAN," said Prof. Barratt. "We're excited to see how the upcoming Phase 3 trials will further define its role." The global Phase 3 BEYOND study is now evaluating zigakibart in a broader population, with primary proteinuria endpoints at 40 weeks and long-term kidney function through 104 weeks.
